医薬品開発の現状と新薬を今後も継続的に臨床現場に届けるために：連携強化におけるneutral platformの役割

抄録

Many new drugs have been approved in the field of neurological diseases over the past decade, including the recent approval of lecanemab (genetical recombination) for Alzheimer disease. On the other hand, “drug loss” (no development of a new drug in Japan, resulting in no access of Japanese patients to the new drug) has recently become more serious. Academia, industry and government have worked to improve the situation but more collaborative efforts among various stakeholders may promote correct understanding of the situations and facilitate a process for improvement. A neutral platform (e.g., Drug Information Association) will play an important role for promoting collaborations among various stakeholders and for constructive discussions toward problem solving. In this article, current situation of drug development in Japan is described and the role of the neutral platform in strengthening collaboration for continuously providing new drugs to patients is discussed, including my personal perspective.